Quick Answer
Connect Biopharma Holdings Ltd reported Total Revenue of $64.0 thousand for fiscal year 2025.
Connect Biopharma Holdings Ltd — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $64.0K -99.8% |
$26.03M | $0.00 | — | — | — |
| Revenue (ASC 606) | $64.0K -99.8% |
$26.03M | $0.00 | — | — | — |
| Net Income | -$55.48M -255.0% |
-$15.63M +74.8% |
-$62.11M | — | — | — |
| Diluted EPS | -$1.00 -257.1% |
-$0.28 +75.2% |
-$1.13 | — | — | — |
| Total Assets | $56.08M -44.6% |
$101.28M -20.5% |
$127.38M -26.8% |
$174.01M -40.2% |
$291.05M -73.2% |
$1.08B |
| Cash and Equivalents | $38.34M -51.0% |
$78.23M -26.0% |
$105.66M | — | — | — |
| Stockholders Equity | $41.98M -54.5% |
$92.17M -9.2% |
$101.50M -35.9% |
$158.42M | — | — |
| R&D Expense | $37.80M +29.2% |
$29.26M -44.8% |
$53.00M -45.1% |
$96.63M +20.0% |
$80.50M -46.7% |
$150.93M +41.8% |
| Operating Income | -$58.07M -158.7% |
-$22.45M +67.5% |
-$69.06M | — | — | — |
| Shares Outstanding | 56.44M +2.0% |
55.35M +0.4% |
55.10M | — | — | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $16.0K | -98.7% | -66.7% |
| Revenue (ASC 606) | September 30, 2025 | $16.0K | -98.7% | -66.7% |
| Net Income | September 30, 2025 | -$17.20M | -33.6% | -33.3% |
| Diluted EPS | September 30, 2025 | -$0.31 | -34.8% | -34.8% |
| Total Assets | September 30, 2025 | $67.36M | — | -18.6% |
| Cash and Equivalents | September 30, 2025 | $37.84M | — | -6.9% |
| Stockholders Equity | September 30, 2025 | $55.37M | -45.0% | -22.4% |
| R&D Expense | September 30, 2025 | $11.11M | +23.3% | +26.6% |
| Operating Income | September 30, 2025 | -$17.68M | -27.7% | -31.7% |
| Shares Outstanding | September 30, 2025 | 55.79M | — | +0.4% |
- Connect Biopharma Holdings Ltd reported Total Revenue of $64.0 thousand for fiscal year 2025.
- Connect Biopharma Holdings Ltd showed a decrease of -99.8% in Total Revenue compared to the prior fiscal year.
- Connect Biopharma Holdings Ltd reported Revenue (ASC 606) of $64.0 thousand for fiscal year 2025.
- Connect Biopharma Holdings Ltd showed a decrease of -99.8% in Revenue (ASC 606) compared to the prior fiscal year.
- Connect Biopharma Holdings Ltd reported Net Income of -$55.48 million for fiscal year 2025.
- Connect Biopharma Holdings Ltd showed a decrease of -255.0% in Net Income compared to the prior fiscal year.
- Connect Biopharma Holdings Ltd reported Diluted EPS of $1.00 per share (loss) for fiscal year 2025.
- Connect Biopharma Holdings Ltd showed a decrease of -257.1% in Diluted EPS compared to the prior fiscal year.
- Connect Biopharma Holdings Ltd reported Total Assets of $56.08 million for fiscal year 2025.
- Connect Biopharma Holdings Ltd showed a decrease of -44.6% in Total Assets compared to the prior fiscal year.
- Connect Biopharma Holdings Ltd reported Cash and Equivalents of $38.34 million for fiscal year 2025.
- Connect Biopharma Holdings Ltd showed a decrease of -51.0% in Cash and Equivalents compared to the prior fiscal year.
- Connect Biopharma Holdings Ltd reported Stockholders Equity of $41.98 million for fiscal year 2025.
- Connect Biopharma Holdings Ltd showed a decrease of -54.5% in Stockholders Equity compared to the prior fiscal year.
- Connect Biopharma Holdings Ltd reported R&D Expense of $37.80 million for fiscal year 2025.
- Connect Biopharma Holdings Ltd showed an increase of +29.2% in R&D Expense compared to the prior fiscal year.
- Connect Biopharma Holdings Ltd reported Operating Income of -$58.07 million for fiscal year 2025.
- Connect Biopharma Holdings Ltd showed a decrease of -158.7% in Operating Income compared to the prior fiscal year.
- Connect Biopharma Holdings Ltd reported Shares Outstanding of 56.44 million shares for fiscal year 2025.
- Connect Biopharma Holdings Ltd showed an increase of +2.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: